{
    "ticker": "AURA",
    "name": "Aura Biosciences, Inc.",
    "description": "Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2015 and based in Cambridge, Massachusetts, Aura is dedicated to advancing its proprietary drug candidates utilizing a unique approach combining viral-targeted therapy with personalized medicine. The company's lead product candidate, AU-011, is designed to treat patients with ocular melanoma, a rare and aggressive form of eye cancer. Through its cutting-edge research and development, Aura aims to improve patient outcomes and quality of life while addressing significant unmet medical needs within oncology. The company employs a multidisciplinary team of scientists and industry veterans committed to translating scientific discoveries into effective cancer therapies. Aura is also exploring various partnerships and collaborations to enhance its research capabilities and expedite the development of its product pipeline. The mission of Aura is to revolutionize cancer treatment by harnessing the potential of targeted therapies and improving the efficacy and safety of existing treatment options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://aurabiosciences.com",
    "ceo": "Brian Stuglik",
    "social_media": {
        "twitter": "https://twitter.com/AuraBiosciences",
        "linkedin": "https://www.linkedin.com/company/aurabiosciences/"
    },
    "investor_relations": "https://investors.aurabiosciences.com",
    "key_executives": [
        {
            "name": "Brian Stuglik",
            "position": "CEO"
        },
        {
            "name": "Kathy F. Markley",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "AU-011"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aura Biosciences, Inc. | Innovative Oncology Therapies",
        "meta_description": "Explore Aura Biosciences, a leader in developing targeted therapies for cancer treatment, including AU-011 for ocular melanoma.",
        "keywords": [
            "Aura Biosciences",
            "Oncology",
            "Cancer Treatment",
            "Ocular Melanoma",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Aura Biosciences known for?",
            "answer": "Aura Biosciences is known for developing innovative therapies for cancer treatment, particularly AU-011 for ocular melanoma."
        },
        {
            "question": "Who is the CEO of Aura Biosciences?",
            "answer": "Brian Stuglik is the CEO of Aura Biosciences, Inc."
        },
        {
            "question": "Where is Aura Biosciences headquartered?",
            "answer": "Aura Biosciences is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Aura's main products?",
            "answer": "Aura's main product is AU-011, a therapy for ocular melanoma."
        },
        {
            "question": "When was Aura Biosciences founded?",
            "answer": "Aura Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "CLVS",
        "ZIOP",
        "NK",
        "BMY"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "EDIT",
        "CRIS"
    ]
}